Drug Pricing
Drug Pricing
Advancing Innovation and Access
We analyze the value that therapies bring to patients and develop novel payment models for rewarding innovation while restraining costs.
Featured Research
Most Medicare Beneficiaries May Pay More for Drugs Under the IRA
Part D plans are abruptly shifting more costs onto beneficiaries as they adjust to the IRA’s new cap on out-of-pocket spending.
Experts: Erin Trish
Related Subtopics
The Schaeffer Center is a nationally recognized leader on drug pricing research, with a particular focus on the economic system that distributes and pays for drugs. Our experts develop effective strategies for containing costs while rewarding new treatments based on the value they provide to patients.
Top Drug Pricing Stories View All
Perspective
Washington Is on the Verge of True PBM Reform
Featured Experts: Neeraj Sood
In The News View All
Healthcare Dive
Blum discusses how staffing challenges at CMS could affect agency work on major initiatives
BBC
Ward interviewed about substantial drops in GLP-1 prices
Featured Experts: Alison Sexton Ward
NBC News
Joyce explains how TrumpRx could better serve consumers
Featured Experts: Geoffrey Joyce
Morning Brew
Qato discusses how new PBM reforms may protect pharmacies and patient access
Featured Experts: Dima M. Qato
The New York Times
New York Times cites Schaeffer research on how TV drug ads could benefit consumers
Featured White Paper
Mitigating the IRA’s Adverse Impacts on the Prescription Drug Market
Although the Inflation Reduction Act of 2022 (IRA) aimed to increase patient access to prescription drugs and decrease spending, researchers warn that it may have unintended negative impacts on patients in the long run. A Schaeffer Center white paper recommends three strategies to mitigate adverse impacts of the IRA.
Read the White PaperTeam View All Drug Pricing Experts
